Francisco Leon, Tolerance Bio CEO
October 15, 2024 07:00 AM EDTUpdated 07:12 AM
Financing
Startups

Tol­er­ance Bio emerges from stealth with $17.2M to ad­vance ther­a­pies de­vel­oped from the thy­mus

Katherine Lewin

News Reporter

Tol­er­ance Bio has launched with an over­sub­scribed $17.2 mil­lion seed round and a goal to de­vel­op ther­a­pies for im­mune-me­di­at­ed dis­eases, from can­cer to trans­plant re­jec­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times